Global healthcare spend to remain stable
Life Sciences Research & Analysis Global healthcare spend to remain stable 01 September 2020 Jing Zhang Milena Izmirlieva Despite projected...
Ms. Izmirlieva heads the Life Sciences research team which comprises senior analysts, analysts and health economists covering developed and emerging markets worldwide. Since joining IHS Markit's Global Insight in 2003 as a research analyst in the Pharma Practice for Western European and Central and Eastern European markets, she has developed extensive knowledge of the healthcare systems and pharmaceutical markets of numerous countries in Europe, North America and various emerging markets. Her main areas of research interest are pricing and reimbursement and market access for originator drugs, the market dynamics for biosimilars and generics, heath system efficiency indicators and health system capacity, and forecasting of healthcare spending and pharmaceutical sales. Before joining IHS Markit, she worked in healthcare marketing communications for the EURO RSCG group in New York, US, and Sofia, Bulgaria, where she specialised in pharmaceutical and medical device companies. She holds a Master of Science degree in Communication with a focus on Science Writing from Iowa State University and a joint BA degree in Journalism and Mass Communication and International Relations from the American University in Bulgaria, and is in the process of completing a Master of Science degree in Health Economics, Policy and Management at the London School of Economics. Ms. Izmirlieva is a regular speaker at pharmaceutical conferences and is often interviewed about pharmaceutical-related issues in the media. She frequently presents peer-reviewed research at ISPOR and has a strong interest in pharmaceutical pricing and reimbursement developments and cost-containment strategies (including international reference pricing). Ms. Izmirlieva is a Fulbright scholarship recipient and member of the following honour societies: Phi Kappa Phi, Alfa Delta Sigma, and Kappa Tau Alfa.
In the race to develop a vaccine against COVID-19, (...)